Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Shares Outstanding (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Shares Outstanding for 6 consecutive years, with $365.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 0.78% to $365.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $365.8 million through Dec 2025, up 0.78% year-over-year, with the annual reading at $365.8 million for FY2025, 0.78% up from the prior year.
  • Shares Outstanding for Q4 2025 was $365.8 million at Lexicon Pharmaceuticals, roughly flat from $365.8 million in the prior quarter.
  • The five-year high for Shares Outstanding was $365.8 million in Q4 2025, with the low at $190.4 million in Q1 2023.
  • Average Shares Outstanding over 3 years is $310.6 million, with a median of $363.0 million recorded in 2024.
  • The sharpest move saw Shares Outstanding skyrocketed 47.69% in 2024, then rose 0.76% in 2025.
  • Over 3 years, Shares Outstanding stood at $245.8 million in 2023, then soared by 47.69% to $363.0 million in 2024, then rose by 0.78% to $365.8 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $365.8 million, $365.8 million, and $365.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.